睿昂基因(688217.SH)2022年度淨利潤4047.36萬元、同比下降14.49%
格隆匯4月9日丨睿昂基因(688217.SH)發佈2022年年度報吿,實現營業收入4.24億元,同比增長45.83%;歸屬於上市公司股東的淨利潤4047.36萬元,同比下降14.49%;歸屬於上市公司股東的扣除非經常性損益的淨利潤3359.91萬元,同比下降2.68%;基本每股收益0.73元。
充分考慮到公司目前在研發項目、固定資產投資、營銷網絡升級等方面的資金需求較大,為更好地維護全體股東的長遠利益,保障公司的可持續發展,公司2022年度擬不派發現金紅利,不送紅股,不以資本公積轉增股本和其他形式的分配,剩餘未分配利潤滾存至下一年度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.